Follow
samar mowafy
samar mowafy
Misr International University
Verified email at miuegypt.edu.eg
Title
Cited by
Cited by
Year
Design, synthesis and in vitro anti-proliferative activity of 4, 6-quinazolinediamines as potent EGFR-TK inhibitors
S Mowafy, NA Farag, KAM Abouzid
European Journal of Medicinal Chemistry 61, 132-145, 2013
482013
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives
S Mowafy, A Galanis, ZM Doctor, RM Paranal, DS Lasheen, NA Farag, ...
Bioorganic & medicinal chemistry 24 (16), 3501-3512, 2016
452016
3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: design, synthesis and biological evaluation
MK Sobhy, S Mowafy, DS Lasheen, NA Farag, KAM Abouzid
Bioorganic chemistry 89, 102988, 2019
342019
Structure-guided development of covalent TAK1 inhibitors
L Tan, D Gurbani, EL Weisberg, JC Hunter, L Li, DS Jones, SB Ficarro, ...
Bioorganic & medicinal chemistry 25 (3), 838-846, 2017
342017
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors
L Tan, D Gurbani, EL Weisberg, DS Jones, S Rao, WD Singer, ...
Bioorganic & medicinal chemistry 25 (4), 1320-1328, 2017
212017
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma
SE Kassab, S Mowafy, AM Alserw, JA Seliem, SM El-Naggar, NN Omar, ...
Journal of enzyme inhibition and medicinal chemistry 34 (1), 1062-1077, 2019
112019
Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to …
MM Abdel-Atty, NA Farag, RAT Serya, KAM Abouzid, S Mowafy
Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 1290-1311, 2021
82021
Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector
CJ Rouse, K Hawkins, N Kabbej, J Dalugdug, A Kunta, MJ Kim, ...
Human Molecular Genetics 32 (3), 417-430, 2023
52023
Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual …
A Raafat, S Mowafy, SM Abouseri, MA Fouad, NA Farag
Computers in Biology and Medicine 146, 105526, 2022
52022
Insights into flibanserin oxidative stress degradation pathway: in silico–in vitro toxicity assessment of its degradates
MF El-Behairy, RM Ahmed, MAA Fayed, S Mowafy, IA Abdallah
New Journal of Chemistry 45 (5), 2620-2630, 2021
52021
Biochemical signatures of disease severity in multiple sulfatase deficiency
LA Adang, S Mowafy, ZM Herbst, Z Zhou, L Schlotawa, K Radhakrishnan, ...
Journal of Inherited Metabolic Disease 47 (2), 374-386, 2024
42024
Structural Basis of Selective Human Indoleamine‐2, 3‐dioxygenase 1 (hIDO1) Inhibition
SE Kassab, S Mowafy
ChemMedChem 16 (20), 3149-3164, 2021
32021
Camptothecin structure simplification elaborated new imidazo [2, 1-b] quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and …
AI Khodair, SM El-Hallouty, B Cagle-White, MHA Aziz, MK Hanafy, ...
European Journal of Medicinal Chemistry 265, 116049, 2024
12024
Lead generation of UPPS inhibitors targeting MRSA: Using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamic simulations
BM Qandeel, S Mowafy, K Abouzid, NA Farag
BMC chemistry 18 (1), 14, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–14